Iovance Biotherapeutics, Inc.
USD4.21
-0.04 (-0.94%)
CEO
Frederick G. Vogt
IPO Date
2010-10-15
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$4.33
Prev. Close
$4.25
Day Low
$4.17
Day High
$4.46
52W Low
$1.67
52W High
$5.63
Market Cap
$1.51B
Volume
10.61M
| 180,632 |
| $0.00 |
| 18 Jun 2026 | Countouriotis Athena | director | A-Award | Acquired | 90,316 | $0.00 |
| 18 Jun 2026 | Maynard Ryan D | director | A-Award | Acquired | 90,316 | $0.00 |
| 18 Jun 2026 | Puri Raj K. | Chief Regulatory Officer | A-Award | Acquired | 15,000 | $0.00 |
| 9 Jun 2026 | Vogt Frederick G | director, officer: Interim CEO & General Counsel | M-Exempt | Acquired | 15,625 | $0.00 |
| 9 Jun 2026 | Vogt Frederick G | director, officer: Interim CEO & General Counsel | F-InKind | Disposed | 6,638 | $4.23 |
| 9 Jun 2026 | Vogt Frederick G | director, officer: Interim CEO & General Counsel | M-Exempt | Disposed | 15,625 | $0.00 |
| 9 Jun 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | M-Exempt | Acquired | 7,813 | $0.00 |
| 9 Jun 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | F-InKind | Disposed | 3,976 | $4.23 |